Some of Januvia generics acquire ‘exclusive sales right’

Published: 2016-01-26 14:05:53

Updated: 2016-01-26 14:05:53

Some of pharmaceutical companies owning generics of antidiabetic Januvia(sitagliptin), a DPP-4 inhibitor, acquired the exclusive sale right. They are sitagliptin single products, sitagliptin-metformin complexes and sitagliptin-metformin release-type products.

The ‘exclusive sale right’ will be opened from 2 September 2023, the next day of the sitagliptin patent expiration date.

The Ministry o...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.